Literature DB >> 27206983

Allele-specific regulation of mutant Huntingtin by Wig1, a downstream target of p53.

Sun-Hong Kim1, Neelam Shahani1, Byoung-Ii Bae2, Juan I Sbodio2, Youjin Chung1, Kazuhiro Nakaso3, Bindu D Paul2, Akira Sawa4,2.   

Abstract

p53 has been implicated in the pathophysiology of Huntington's disease (HD). Nonetheless, the molecular mechanism of how p53 may play a unique role in the pathology remains elusive. To address this question at the molecular and cellular biology levels, we initially screened differentially expressed molecules specifically dependent on p53 in a HD animal model. Among the candidate molecules, wild-type p53-induced gene 1 (Wig1) is markedly upregulated in the cerebral cortex of HD patients. Wig1 preferentially upregulates the level of mutant Huntingtin (Htt) compared with wild-type Htt. This allele-specific characteristic of Wig1 is likely to be explained by higher affinity binding to mutant Htt transcripts than normal counterpart for the stabilization. Knockdown of Wig1 level significantly ameliorates mutant Htt-elicited cytotoxicity and aggregate formation. Together, we propose that Wig1, a key p53 downstream molecule in HD condition, play an important role in stabilizing mutant Htt mRNA and thereby accelerating HD pathology in the mHtt-p53-Wig1 positive feedback manner.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27206983      PMCID: PMC6086561          DOI: 10.1093/hmg/ddw115

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  48 in total

1.  Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.

Authors:  F C Nucifora ; M Sasaki; M F Peters; H Huang; J K Cooper; M Yamada; H Takahashi; S Tsuji; J Troncoso; V L Dawson; T M Dawson; C A Ross
Journal:  Science       Date:  2001-03-23       Impact factor: 47.728

Review 2.  p53 regulation of metabolic pathways.

Authors:  Eyal Gottlieb; Karen H Vousden
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-02       Impact factor: 10.005

3.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

4.  Wig-1, a new p53-induced gene encoding a zinc finger protein.

Authors:  S Varmeh-Ziaie; I Okan; Y Wang; K P Magnusson; P Warthoe; M Strauss; K G Wiman
Journal:  Oncogene       Date:  1997-11-27       Impact factor: 9.867

5.  Regulation of PTEN transcription by p53.

Authors:  V Stambolic; D MacPherson; D Sas; Y Lin; B Snow; Y Jang; S Benchimol; T W Mak
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

6.  The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity.

Authors:  Cristina Méndez-Vidal; Margareta T Wilhelm; Fredrik Hellborg; Wang Qian; Klas G Wiman
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

7.  Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability.

Authors:  Andrei V Budanov; Tzipora Shoshani; Alexander Faerman; Elena Zelin; Iris Kamer; Hagar Kalinski; Svetlana Gorodin; Alla Fishman; Ayelet Chajut; Paz Einat; Rami Skaliter; Andrei V Gudkov; Peter M Chumakov; Elena Feinstein
Journal:  Oncogene       Date:  2002-09-05       Impact factor: 9.867

8.  Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.

Authors:  M DiFiglia; M Sena-Esteves; K Chase; E Sapp; E Pfister; M Sass; J Yoder; P Reeves; R K Pandey; K G Rajeev; M Manoharan; D W Y Sah; P D Zamore; N Aronin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-16       Impact factor: 11.205

9.  Sustained effects of nonallele-specific Huntingtin silencing.

Authors:  Valérie Drouet; Valérie Perrin; Raymonde Hassig; Noëlle Dufour; Gwennaelle Auregan; Sandro Alves; Gilles Bonvento; Emmanuel Brouillet; Ruth Luthi-Carter; Philippe Hantraye; Nicole Déglon
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

Review 10.  Normal huntingtin function: an alternative approach to Huntington's disease.

Authors:  Elena Cattaneo; Chiara Zuccato; Marzia Tartari
Journal:  Nat Rev Neurosci       Date:  2005-12       Impact factor: 34.870

View more
  5 in total

Review 1.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

2.  Tolfenamic acid inhibits ROS-generating oxidase Nox1-regulated p53 activity in intrastriatal injection of malonic acid rats.

Authors:  Xin Yang; Heling Zhang; Tong Qu; Yi Wang; Yongxian Zhong; Yuchen Yan; Xuefei Ji; Tiayan Chi; Peng Liu; Libo Zou
Journal:  J Physiol Sci       Date:  2022-07-18       Impact factor: 2.257

Review 3.  Molecular Pathophysiological Mechanisms in Huntington's Disease.

Authors:  Anamaria Jurcau
Journal:  Biomedicines       Date:  2022-06-17

4.  WIG1 is crucial for AGO2-mediated ACOT7 mRNA silencing via miRNA-dependent and -independent mechanisms.

Authors:  Hyung Chul Lee; Seung Hee Jung; Hyun Jung Hwang; Donghee Kang; Supriyo De; Dawood B Dudekula; Jennifer L Martindale; Byungkyu Park; Seung Kuk Park; Eun Kyung Lee; Jeong-Hwa Lee; Sunjoo Jeong; Kyungsook Han; Heon Joo Park; Young-Gyu Ko; Myriam Gorospe; Jae-Seon Lee
Journal:  Nucleic Acids Res       Date:  2017-06-20       Impact factor: 16.971

Review 5.  Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.

Authors:  Chunchen Xiang; Shun Zhang; Xiaoyu Dong; Shuang Ma; Shuyan Cong
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.